Literature DB >> 30315111

Electrostatic repulsion causes anticooperative DNA binding between tumor suppressor ETS transcription factors and JUN-FOS at composite DNA sites.

Bethany J Madison1,2, Kathleen A Clark1,2, Niraja Bhachech1,2, Peter C Hollenhorst3, Barbara J Graves4,2,5, Simon L Currie1,2.   

Abstract

Many different transcription factors (TFs) regulate gene expression in a combinatorial fashion, often by binding in close proximity to each other on composite cis-regulatory DNA elements. Here, we investigated how ETS TFs bind with the AP1 TFs JUN-FOS at composite DNA-binding sites. DNA-binding ability with JUN-FOS correlated with the phenotype of ETS proteins in prostate cancer. We found that the oncogenic ETS-related gene (ERG) and ETS variant (ETV) 1/4/5 subfamilies co-occupy ETS-AP1 sites with JUN-FOS in vitro, whereas JUN-FOS robustly inhibited DNA binding by the tumor suppressors ETS homologous factor (EHF) and SAM pointed domain-containing ETS TF (SPDEF). EHF bound ETS-AP1 DNA with tighter affinity than ERG in the absence of JUN-FOS, possibly enabling EHF to compete with ERG and JUN-FOS for binding to ETS-AP1 sites. Genome-wide mapping of EHF- and ERG-binding sites in prostate epithelial cells revealed that EHF is preferentially excluded from closely spaced ETS-AP1 DNA sequences. Structural modeling and mutational analyses indicated that adjacent positively charged surfaces from EHF and JUN-FOS use electrostatic repulsion to disfavor simultaneous DNA binding. Conservation of positive residues on the JUN-FOS interface identified E74-like ETS TF 1 (ELF1) as an additional ETS TF exhibiting anticooperative DNA binding with JUN-FOS, and we found that ELF1 is frequently down-regulated in prostate cancer. In summary, divergent electrostatic features of ETS TFs at their JUN-FOS interface enable distinct binding events at ETS-AP1 DNA sites, which may drive specific targeting of ETS TFs to facilitate distinct transcriptional programs.
© 2018 Madison et al.

Entities:  

Keywords:  AP1 transcription factor (AP1); ETS transcription factor family; JUN–FOS complex; gene expression; prostate cancer; protein–DNA interaction; protein–protein interaction; transcriptional regulation; tumor suppressor gene

Mesh:

Substances:

Year:  2018        PMID: 30315111      PMCID: PMC6290139          DOI: 10.1074/jbc.RA118.003352

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  Structure of HoxA9 and Pbx1 bound to DNA: Hox hexapeptide and DNA recognition anterior to posterior.

Authors:  Nicole A LaRonde-LeBlanc; Cynthia Wolberger
Journal:  Genes Dev       Date:  2003-08-15       Impact factor: 11.361

2.  Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells.

Authors:  Peter C Hollenhorst; Mary W Ferris; Megan A Hull; Heejoon Chae; Sun Kim; Barbara J Graves
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

3.  Interaction of murine ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif.

Authors:  J A Nye; J M Petersen; C V Gunther; M D Jonsen; B J Graves
Journal:  Genes Dev       Date:  1992-06       Impact factor: 11.361

4.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

5.  Structured and disordered regions cooperatively mediate DNA-binding autoinhibition of ETS factors ETV1, ETV4 and ETV5.

Authors:  Simon L Currie; Desmond K W Lau; Jedediah J Doane; Frank G Whitby; Mark Okon; Lawrence P McIntosh; Barbara J Graves
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

6.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

7.  Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer.

Authors:  R Cangemi; A Mensah; V Albertini; A Jain; M Mello-Grand; G Chiorino; C V Catapano; G M Carbone
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

8.  Crystal structure of the heterodimeric bZIP transcription factor c-Fos-c-Jun bound to DNA.

Authors:  J N Glover; S C Harrison
Journal:  Nature       Date:  1995-01-19       Impact factor: 49.962

9.  Comparison of MAPK specificity across the ETS transcription factor family identifies a high-affinity ERK interaction required for ERG function in prostate cells.

Authors:  Nagarathinam Selvaraj; Vivekananda Kedage; Peter C Hollenhorst
Journal:  Cell Commun Signal       Date:  2015-02-19       Impact factor: 5.712

10.  Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.

Authors:  Akash Kumar; Ilsa Coleman; Colm Morrissey; Xiaotun Zhang; Lawrence D True; Roman Gulati; Ruth Etzioni; Hamid Bolouri; Bruce Montgomery; Thomas White; Jared M Lucas; Lisha G Brown; Ruth F Dumpit; Navonil DeSarkar; Celestia Higano; Evan Y Yu; Roger Coleman; Nikolaus Schultz; Min Fang; Paul H Lange; Jay Shendure; Robert L Vessella; Peter S Nelson
Journal:  Nat Med       Date:  2016-02-29       Impact factor: 53.440

View more
  5 in total

1.  Salt bridge dynamics in protein/DNA recognition: a comparative analysis of Elk1 and ETV6.

Authors:  Tam D Vo; Amelia L Schneider; W David Wilson; Gregory M K Poon
Journal:  Phys Chem Chem Phys       Date:  2021-06-23       Impact factor: 3.676

2.  EHF is a novel regulator of cellular redox metabolism and predicts patient prognosis in HNSCC.

Authors:  Akinsola Oyelakin; Kasturi Bala Nayak; Alexandra Ruth Glathar; Christian Gluck; Theresa Wrynn; Antonio Tugores; Rose-Anne Romano; Satrajit Sinha
Journal:  NAR Cancer       Date:  2022-05-27

3.  The Transcription Factor ERG Regulates Super-Enhancers Associated With an Endothelial-Specific Gene Expression Program.

Authors:  Viktoria Kalna; Youwen Yang; Claire R Peghaire; Karen Frudd; Rebecca Hannah; Aarti V Shah; Lourdes Osuna Almagro; Joseph J Boyle; Berthold Göttgens; Jorge Ferrer; Anna M Randi; Graeme M Birdsey
Journal:  Circ Res       Date:  2019-04-26       Impact factor: 17.367

Review 4.  Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer.

Authors:  Francesca Lorenzin; Francesca Demichelis
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

5.  ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling axis.

Authors:  Tiansuo Zhao; Di Xiao; Fanjie Jin; Xugang Sun; Jie Yu; Hongwei Wang; Jing Liu; Wenrun Cai; Chongbiao Huang; Xiuchao Wang; Song Gao; Zhe Liu; Shengyu Yang; Chuntao Gao; Jihui Hao
Journal:  Br J Cancer       Date:  2022-08-19       Impact factor: 9.075

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.